|
Response rate to bisphosphonates depends on 25-D level. |
 |
|
EurekAlert: Patients with a hydroxyvitamin D level of 33 ng/mL and above had a sevenfold greater likelihood of having a favorable response to bisphosphonate therapy than below that level, they found. "This value of at least 33 ng/mL is higher than the level considered as "adequate" by the Institute of Medicine report for the general population and most likely requires a vitamin D intake higher than 600 IU for this therapeutic outcome," Bockman said. "In the future, I think we're going to see vitamin D recommendations based on specific conditions."
|